Elicio Therapeutics Grants 22,400 Stock Options to Attract New Employees
- Stock Option Incentive: On January 15, 2026, Elicio Therapeutics granted 22,400 inducement stock options to two new employees to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4), which is expected to enhance the company's talent acquisition and team strength.
- Option Pricing: Each stock option is priced at $7.81 per share based on the closing price on the grant date, which will allow employees to gradually acquire company shares over four years, thereby increasing employee loyalty in the long term.
- Clinical Research Progress: Elicio's ELI-002 immunotherapy demonstrated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months in a randomized trial for mKRAS-positive pancreatic cancer, indicating its potential in cancer treatment and likely driving future market demand.
- Technological Innovation: Elicio's AMP technology aims to enhance the education and activation of cancer-specific T cells, which is expected to provide the company with a strategic advantage in the competitive biotechnology market, particularly in the field of immunotherapy for high-prevalence cancers.
Trade with 70% Backtested Accuracy
Analyst Views on ELTX
About ELTX
About the author
Elicio Therapeutics Grants 22,400 Stock Options to Attract New Employees
- Stock Option Incentive: On January 15, 2026, Elicio Therapeutics granted 22,400 inducement stock options to two new employees to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4), which is expected to enhance the company's talent acquisition and team strength.
- Option Pricing: Each stock option is priced at $7.81 per share based on the closing price on the grant date, which will allow employees to gradually acquire company shares over four years, thereby increasing employee loyalty in the long term.
- Clinical Research Progress: Elicio's ELI-002 immunotherapy demonstrated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months in a randomized trial for mKRAS-positive pancreatic cancer, indicating its potential in cancer treatment and likely driving future market demand.
- Technological Innovation: Elicio's AMP technology aims to enhance the education and activation of cancer-specific T cells, which is expected to provide the company with a strategic advantage in the competitive biotechnology market, particularly in the field of immunotherapy for high-prevalence cancers.
Elicio Grants 157,193 Stock Options to Attract New Employees
- Employee Incentive Program: On December 15, 2025, Elicio granted 157,193 inducement stock options to three new employees, aiming to attract talent while complying with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to talent acquisition.
- Stock Option Details: Each stock option has an exercise price of $8.52 per share, based on the closing price on the grant date, with vesting over four years, reflecting the company's recognition of long-term employee contributions.
- Clinical Development Outlook: Elicio focuses on developing immunotherapies for high-prevalence cancers, particularly ELI-002 for mKRAS-positive pancreatic and colorectal cancers, aiming to meet market demand through low-cost and rapid production, thereby enhancing competitive positioning.
- Future Expansion Plans: Elicio intends to expand ELI-002 to other mKRAS-positive cancers, further enriching its pipeline and strengthening its market position to address the growing demand for cancer treatments.
Elicio Announces Robust T Cell Responses in Phase 2 Cancer Vaccine Trial
Trial Results: Elicio Therapeutics announced that 99% of patients in its Phase 2 AMPLIFY-7P trial showed strong mKRAS-specific T cell responses after treatment with the investigational cancer vaccine ELI-002 7P, with immune responses increasing 145-fold from baseline.
Future Expectations: The company anticipates final disease-free survival data from the trial by the fourth quarter of 2025, and an independent monitoring committee has recommended that the trial continue without changes, indicating potential efficacy.
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics KOL Event: Elicio Therapeutics will host a virtual event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic cancer, featuring insights from leading experts and focusing on their lead product candidate, ELI-002, which is currently in a Phase 2 trial.
ELI-002 and AMP Platform: ELI-002 is an investigational cancer vaccine targeting KRAS mutations, utilizing Elicio's proprietary amphiphile (AMP) platform designed to enhance immune responses by delivering therapeutics directly to lymph nodes, with plans for future expansion into other cancer indications.
Elicio Therapeutics Secures $10 Million in Financing
Funding Announcement: Elicio Therapeutics has secured a $10 million senior secured promissory note to support operations until Q1 2026, coinciding with the anticipated interim analysis of their AMPLIFY-7P Phase 2 trial in Q3 2025.
Product Development: The company is advancing its lead cancer vaccine candidate, ELI-002, targeting mKRAS-driven tumors, and plans to explore additional indications and combination therapies for pancreatic and colorectal cancers.
Elicio Therapeutics Grants 22,400 Stock Options to Attract New Employees
- Stock Option Incentive: On January 15, 2026, Elicio Therapeutics granted 22,400 inducement stock options to two new employees to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4), which is expected to enhance the company's talent acquisition and team strength.
- Option Pricing: Each stock option is priced at $7.81 per share based on the closing price on the grant date, which will allow employees to gradually acquire company shares over four years, thereby increasing employee loyalty in the long term.
- Clinical Research Progress: Elicio's ELI-002 immunotherapy demonstrated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months in a randomized trial for mKRAS-positive pancreatic cancer, indicating its potential in cancer treatment and likely driving future market demand.
- Technological Innovation: Elicio's AMP technology aims to enhance the education and activation of cancer-specific T cells, which is expected to provide the company with a strategic advantage in the competitive biotechnology market, particularly in the field of immunotherapy for high-prevalence cancers.
Elicio Grants 157,193 Stock Options to Attract New Employees
- Employee Incentive Program: On December 15, 2025, Elicio granted 157,193 inducement stock options to three new employees, aiming to attract talent while complying with Nasdaq Listing Rule 5635(c)(4), highlighting the company's commitment to talent acquisition.
- Stock Option Details: Each stock option has an exercise price of $8.52 per share, based on the closing price on the grant date, with vesting over four years, reflecting the company's recognition of long-term employee contributions.
- Clinical Development Outlook: Elicio focuses on developing immunotherapies for high-prevalence cancers, particularly ELI-002 for mKRAS-positive pancreatic and colorectal cancers, aiming to meet market demand through low-cost and rapid production, thereby enhancing competitive positioning.
- Future Expansion Plans: Elicio intends to expand ELI-002 to other mKRAS-positive cancers, further enriching its pipeline and strengthening its market position to address the growing demand for cancer treatments.
Elicio Announces Robust T Cell Responses in Phase 2 Cancer Vaccine Trial
Trial Results: Elicio Therapeutics announced that 99% of patients in its Phase 2 AMPLIFY-7P trial showed strong mKRAS-specific T cell responses after treatment with the investigational cancer vaccine ELI-002 7P, with immune responses increasing 145-fold from baseline.
Future Expectations: The company anticipates final disease-free survival data from the trial by the fourth quarter of 2025, and an independent monitoring committee has recommended that the trial continue without changes, indicating potential efficacy.
HC Wainwright & Co. Maintains Buy on Elicio Therapeutics, Raises Price Target to $13
Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders succeed in the stock market.
Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and insights.
Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer
Elicio Therapeutics KOL Event: Elicio Therapeutics will host a virtual event on June 25, 2025, to discuss the treatment landscape for mutant-KRAS driven pancreatic cancer, featuring insights from leading experts and focusing on their lead product candidate, ELI-002, which is currently in a Phase 2 trial.
ELI-002 and AMP Platform: ELI-002 is an investigational cancer vaccine targeting KRAS mutations, utilizing Elicio's proprietary amphiphile (AMP) platform designed to enhance immune responses by delivering therapeutics directly to lymph nodes, with plans for future expansion into other cancer indications.
Elicio Therapeutics Secures $10 Million in Financing
Funding Announcement: Elicio Therapeutics has secured a $10 million senior secured promissory note to support operations until Q1 2026, coinciding with the anticipated interim analysis of their AMPLIFY-7P Phase 2 trial in Q3 2025.
Product Development: The company is advancing its lead cancer vaccine candidate, ELI-002, targeting mKRAS-driven tumors, and plans to explore additional indications and combination therapies for pancreatic and colorectal cancers.
